No survival benefit of annual ovarian cancer screening in low-risk women
Neither yearly transvaginal ultrasound nor multimodal screenings were associated with a significant reduction of deaths from tubal and ovarian cancer in women who were considered low risk for the disease, according to recently published data from a long-term study.
The results — which were published in The Lancet — demonstrate that screening the general population for tubal and ovarian cancer each year is not needed, according to the study authors.
“The case fatality for ovarian cancer is high meaning that a high proportion of patients diagnosed with it end up dying from the disease — mostly from advanced-stage disease,” Dr. Kristine Zanotti, program director of gynecologic oncology at University Hospitals Cleveland Medical Center, said in an interview with CURE®. “We have been looking for an effective screening method for a very long time.”
Read more from Contemporary OBGYN by Ryan McDonald about No survival benefit of annual ovarian cancer screening in low-risk women
David A Litman/Shutterstock.com